Earnings summaries and quarterly performance for Pediatrix Medical Group.
Executive leadership at Pediatrix Medical Group.
Board of directors at Pediatrix Medical Group.
Research analysts who have asked questions during Pediatrix Medical Group earnings calls.
AR
Albert Rice
UBS
3 questions for MD
Also covers: ACHC, AMED, AMN +20 more
JS
Jack Slevin
Jefferies Financial Group Inc.
3 questions for MD
Also covers: AGL, AMN, ASTH +8 more
PC
Pito Chickering
Deutsche Bank
2 questions for MD
Also covers: ACHC, AHCO, AVAH +18 more
BM
Benjamin Mayo
Leerink Partners
1 question for MD
Also covers: ACHC, AGL, AMED +10 more
Benjamin Shaver
Deutsche Bank AG
1 question for MD
JS
Jack Senft
William Blair
1 question for MD
Also covers: AMWL, HCSG, LFST +3 more
KR
Kieran Ryan
Deutsche Bank
1 question for MD
Also covers: AHCO, AVAH, BTSG +3 more
Tao Qiu
Macquarie Group
1 question for MD
Also covers: ADUS, AMED, BKD +5 more
Whit Mayo
Leerink Partners
1 question for MD
Also covers: ACHC, AHCO, ALHC +11 more
Recent press releases and 8-K filings for MD.
Pediatrix Medical Group Reports Strong Q3 2025 Results and Updates Full-Year Guidance
MD
Earnings
Guidance Update
Share Buyback
- Pediatrix Medical Group reported Q3 2025 adjusted EBITDA of $87 million, exceeding expectations, and provided a full-year 2025 adjusted EBITDA outlook of $270-$290 million.
- The company generated $138 million in operating cash flow in Q3 2025, ending the quarter with $340 million in cash and net debt of just over $260 million, resulting in net leverage of just under one times.
- Pediatrix repurchased 1.2 million shares in Q3 2025, using $21 million in cash, and invested $19 million to acquire several neonatology, MFM, and OB hospitalist practices.
- Q3 performance was driven by 8% same-unit growth, with pricing up about 7.5% due to strong RCM cash collections, increased patient acuity, contract administrative fees, and favorable payer mix.
Nov 3, 2025, 2:00 PM
Pediatrix Medical Group Reports Q3 2025 Results and Raises Full Year Adjusted EBITDA Outlook
MD
Earnings
Guidance Update
- Pediatrix Medical Group reported net revenue of $493 million and Adjusted EBITDA of $87 million for the third quarter ended September 30, 2025. Diluted earnings per share (EPS) was $0.84, and Adjusted EPS was $0.67.
- For the nine months ended September 30, 2025, the company generated revenue of $1.42 billion and Adjusted EBITDA of $209.7 million.
- The company raised its full year 2025 Adjusted EBITDA outlook, now anticipating a range of $270 million to $290 million.
- As of September 30, 2025, Pediatrix had cash and cash equivalents of $340.1 million and total debt outstanding of $602 million.
Nov 3, 2025, 11:50 AM
Pediatrix Medical Group Reports Strong Q3 2025 Results and Raises Full-Year EBITDA Guidance
MD
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Pediatrix Medical Group reported strong Q3 2025 financial results, with revenue of approximately $493 million and earnings per share of $0.84, surpassing analyst expectations.
- The company's net income rose significantly to about $72 million, and Q3 Adjusted EBITDA increased to $87 million from $60.2 million in the prior-year period, reflecting favorable same-unit results.
- Pediatrix raised its full-year adjusted EBITDA guidance to a range of $270 million to $290 million, indicating confidence despite ongoing healthcare industry uncertainties.
- The company's shares are trading at 9 times next year’s expected earnings, up from 7 times three months earlier, and are approaching their $17 median price target.
Nov 3, 2025, 11:23 AM
Pediatrix Medical Group Reports Strong Third Quarter 2025 Results and Raises Full Year Adjusted EBITDA Outlook
MD
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Pediatrix Medical Group reported net revenue of $493 million, net income of $72 million, and Adjusted EBITDA of $87 million for the third quarter ended September 30, 2025.
- Diluted earnings per share (EPS) for the quarter was $0.84, with Adjusted EPS at $0.67.
- These results were driven by 8.0 percent growth in same-unit net revenue, attributed to strong collection activity, higher patient acuity, and a favorable payor mix.
- The company raised its full-year 2025 Adjusted EBITDA outlook to a range of $270 million to $290 million.
Nov 3, 2025, 11:00 AM
Quarterly earnings call transcripts for Pediatrix Medical Group.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more